GIBRALTAR BSN AGGRESSIVE FUND

September 2022

Investment Objective

To achieve consistent and above average capital appreciation over the medium to long-term by investing in companies with market capitalization of not more than RM750 million at the time of acquisition.

Investor Profile

The fund is suitable for investors who are willing to accept higher level of risk in order to obtain higher growth of their capital and have a medium to long term investment horizon.

Fund Manager

UOB Asset Management (Malaysia)

Fund Details

Unit NAV	RM3.5950
Fund Size	RM74.2 million
Inception Date	1 April 2005
Management Fee	1.50% per annum

Top 10 Holdings

Berjaya Food	7.0%
Formosa Prosonic	6.6%
D&O Green Technologies	5.8%
Dufu Tech	5.7%
Thong Guan	4.8%
Pentamaster	3.9%
PIE Industrial	3.8%
Duopharma Biotech	3.8%
Frontken	3.7%
Power Root	3.7%

Data as at 31 August 2022

Cumulative Performance Since Inception as at 31 August 2022



Performance Table as at 31 August 2022

	1 month	3 months	6 months	YTD	1 year	3 years	5 years	Since inception
Fund	-0.3%	-2.1%	-5.3%	-17.7%	-14.9%	38.5%	41.0%	656.8%
Benchmark	0.9%	-4.1%	-6.4%	-5.4%	-8.0%	-5.7%	-15.2%	82.4%

- *Benchmark: FTSE Bursa Malaysia Emas Index*
- *Source: Bloomberg & Gibraltar BSN Life Bhd*

Past performance is not indicative of future performance and the performance of the fund is not guaranteed.

Portfolio Composition as at 31 August 2022



Source: UOBAM

GIBRALTAR BSN AGGRESSIVE FUND

September 2022

Manager's Comment

For August 2022, the Fund's NAV/unit decreased by 0.3%, underperformed the FBM EMAS which increased by 0.9% mainly due to the Fund's overweight position in the technology sector and underweight position in the financial sector.

It was a mixed month for global equities with declines skewed to the United States and mainland China. US equities declined in August after Jerome Powell's hawkish comments at the Jackson Hole conference. Meanwhile, mainland China's south-western metropolis of Chengdu placed 21 million people under lockdown as the country continued to practice its stringent zero-COVID policy.

On the local front, the FBM KLCI Index gained 1.3% month-on-month to close at 1,512 points. Foreign investors continued to be net buyers of Malaysian equities in August amounting to RM2 billion, an increase from net buying of RM175 million in July. The best performing sectors were energy, utilities and telecommunications while the worst performing sectors were healthcare, technology and REITs.

Malaysia's 2Q22 GDP grew 8.9% year-on-year fueled by a recovery in domestic demand amid a normalizing economy and the reopening of international borders. This brought the cumulative 1H22 GDP growth to 6.9% year on year, at the upper end of Bank Negara Malaysia's forecast. The central bank maintained its 2022 GDP forecast at 5.3-6.3%, with a bias to the upper end of its projection range.

All in, we continue to be cautious on markets due to headwinds from tightening monetary policy, elevated inflation and slowdown in the global economy. Our defensive stance remains. We prefer value/reopening stocks at this juncture.

Disclaimer

This report is for information only and is purely a product summary. Please refer to the product fact sheet available at www.gibraltarbsn.com for further details. This report shall not be reproduced, copied, circulated or forwarded either in part or otherwise to any persons howsoever without the prior written consent of Gibraltar BSN Life Berhad.

The opinions and information contained herein are based on the latest available data which is believed to be reliable. It is not to be construed as an offer, invitation or solicitation to buy or sell any securities or financial instruments covered by this report. Gibraltar BSN Life Berhad does not warrant the accuracy of anything stated herein in any manner whatsoever and no reliance upon such statement by anyone shall give rise to any claim whatsoever against Gibraltar BSN Life Berhad and/or its associated persons. Gibraltar BSN Life Berhad and/or its associated persons may from time to time have an interest in the securities or financial instruments mentioned by this report. Past Performance of the Funds mentioned in the Report is not an indication of its future performance. Investors/policy holders should rely on their own evaluation to assess the merits and risks of the investment. In considering to invest in an investment-linked fund, investors/policy holders who are in doubt on the action to be taken should consult a professional adviser. Investors/Policy holders have to take note that investments can fluctuate in value and values may fall as well as rise and an investor/policy holder may not get back the amount invested.